Nuclear focal adhesion kinase (FAK) is a potentially important regulator of gene expression in cancer, impacting both cellular function and the composition of the surrounding tumor microenvironment. Here we report in a murine model of skin squamous cell carcinoma (SCC) that nuclear FAK regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), and that this regulates SCC cell cycle progression and tumor growth in vivo. Furthermore, we identified a novel molecular complex between FAK and Runx1 in the nucleus of SCC cells and showed that FAK interacted with a number of Runx1 regulatory proteins, including Sin3a and other epigenetic modifiers known to alter Runx1 transcriptional function through post-translational modification. These findings provide important new insights into the role of FAK as a scaffolding protein in molecular complexes that regulate gene transcription.
Introduction
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that controls diverse cellular functions including cell adhesion, migration, invasion, polarity, proliferation, and survival (1, 2) . FAK is therefore involved in a number of processes that can impact on the malignant phenotype. Deletion of fak in mouse models of cancer has shown a requirement for FAK in tumor formation and progression (3) (4) (5) (6) (7) (8) (9) .
Over-expression of FAK has also been reported in a number of human epithelial tumors (10) (11) (12) , and it has therefore emerged as a potential target for cancer therapy, with a number of FAK kinase inhibitors currently being developed (13) .
FAK was identified as a protein highly phosphorylated in response to integrin activation and primarily located at cell-extracellular matrix adhesion sites termed focal adhesions (1) . Recent reports have also identified that FAK contains nuclear localization signals within the F2 lobe of the four-point-one, ezrin, radixin, moesin (FERM) domain (14) and a nuclear export signal within the kinase domain (15) .
Therefore, FAK can translocate to the nucleus, where its function remains poorly characterized. Within the nucleus, the FAK FERM domain can bind to the transcription factors p53 and GATA4, resulting in their turnover and inactivation, thereby controlling cell survival and inflammatory signals (14, 16) . Recently, we reported that nuclear FAK was tethered to chromatin and regulated the expression of chemokines and cytokines, including Ccl5 and TGF2, that contribute to establishment of an immuno-suppressive tumor environment through driving elevated intra-tumoral regulatory T-cell numbers (17) . Therefore, nuclear FAK protein complexes can act to regulate transcriptional programs important in controlling cellular responses and the composition of the tumor immune environment.
Runt-related transcription factor 1 (Runx1; also known as AML1) is one of a Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 14, 2017; DOI: 10.1158/0008-5472. family of three transcription factors (Runx1 -3) that can either activate or repress transcription depending on the target gene, cell type, and associated co-factors (18, 19) . It has been shown to have a critical role in hematopoiesis and hematopoietic function (20) , and is essential for mammalian development (21) . In the context of cancer, Runx1 is best known for its role in acute myeloid leukemia (AML) where it is frequently found mutated (18) . In recent years it has also become clear that Runx1 plays an important role in solid epithelial malignancies. For example, Runx1 deficiency impairs mouse skin tumorigenesis (22) , while in contrast it acts as a tumor suppressor in the Apc Min mouse model of colorectal carcinogenesis (23) . Therefore, it has an important but context dependent function in cancer. Here, we identify a novel molecular complex between FAK and Runx1 in the nucleus of skin squamous cell carcinoma (SCC) cells. We show that nuclear FAK and Runx1 cooperate to regulate expression of IGFBP3, and that IGFBP3 regulates cell cycle progression and tumor growth in vivo. Using proteomics and network biology approaches, we identify that nuclear FAK interacts with a number of Runx1 regulatory proteins that can alter Runx1 transcriptional function through post-translational modification. Further, we identify a novel interaction between nuclear FAK and Sin3a, a core component of the Sin3a/HDAC co-repressor complex, and show that Runx1/Sin3a interaction is enhanced in SCC FAK-wt cells. This study provides new insights into the potential mechanisms through which nuclear FAK regulates transcription factor function to control cell behavior. 
Materials and Methods
Materials. All antibodies used are listed in Supplementary Materials and Methods.
All siRNA was purchased from Dharmacon and shRNA from Open Biosystems.
Cell lines. Cell lines used in this study were generated, authenticated and characterized as previously described (17, 24) . Cells were pathogen tested in September 2016 using the ImpactIII test (Idex Bioresearch) and were negative for all pathogens. Cell lines are routinely tested for mycoplasma every 2-3 months in-house and have never been found to be mycoplasma positive. Cell lines are cultured for no more than 3 months following freeze thawing. Runx1 or scrambled siRNA was transiently transfected into SCC cells using HiPerFect (Qiagen). Cells were left for 3 days and then immunoblotting or (q)RT-PCR analysis was carried out. Cell lines stably expressing FUCCI, Runx1, or empty-vector shRNA were generated by lentiviral infection and selected in 2 µg/ml puromycin.
Generation of nuclear-targeting FAK mutants. Point mutations were introduced
into wild-type FAK in three different combinations, (1) R177A and R178A, (2) K190A and K191A, (3) K216A and K218A, using site-directed mutagenesis as previously described (17) . Primer sequences are listed in Supplementary Materials and Methods.
Quantitative RT-PCR. RNA extracts were obtained using an RNeasy kit (Qiagen), following manufacturer's instructions. cDNA was made using a first-strand cDNA synthesis kit (Invitrogen). (q)RT-PCR was performed as previously described (17) .
Analysis was performed using Rotor-Gene software, and expression relative to B2M was calculated using Excel (Microsoft). Standard PCR was performed using the above For staining, sections were removed from the −20C freezer, and 50 l of fixative was applied directly onto the tissue. Sections were incubated for 8 minutes at 4C and then the fixative removed and the slides allowed to equilibrate to room temperature for approximately 10-20 minutes. Sections were then rehydrated in PBS for 10 minutes. The area of tissue was surrounded with a hydrophobic barrier pen and blocked using 1% horse serum in PBS for 30 minutes at room temperature. Tissue was then incubated with anti-CD31 antibody (BD Biosciences, 1:100 dilution in incubation buffer (1% bovine serum albumin, 1% normal donkey serum, 0.3% Triton X-100, 0.01% sodium azide in PBS)) overnight at 4C. Slides were washed three times for 15 minutes with PBS, and then incubated with anti-rat Alexa Fluor 594conjugated secondary antibody (Molecular Probes, ThermoFisher Scientific) diluted at 1:200 in incubation buffer for 1 hour at room temperature. Slides were washed three times for 15 minutes in PBS and then counter-stained with DAPI for 5 minutes.
Slides were washed once for 15 minutes in PBS and mounted in VectaShield anti-fade mounting media (Vectorlabs). Images were acquired using an Olympus FV1000 confocal microscope. Integrated Discovery (version 6.8) (28) . Pathway terms with Benjamini-Hochbergcorrected P-value < 0.01 were considered significantly overrepresented.
Subcutaneous tumor growth. 2.5 × 10 5 cells were injected subcutaneously into each flank of immune-compromised CD-1 nude mice, and tumor growth measured twice weekly using calipers. Measurements were taken from three mice (each bearing two tumors) for each cell line, and the volume of the tumor (v) was calculated in Excel using the formula v = 4/3.π.r 3 . Data were graphed and statistics calculated using Prism (GraphPad).
In vivo cell cycle analyses. Optical window chambers were implanted onto CD-1 nude mice as described previously (29) . All animal work was carried out in compliance with UK Home Office guidelines. 1 × 10 6 FUCCI-expressing SCC cells were injected into the dermis and at the time of window implantation. 24 hours later, mice were anaesthetized using an isoflurane-oxygen mix and three-dimensional image stacks acquired using an Olympus FV1000 confocal microscope. Image analysis was performed using the spot detection tool in Imaris (Bitplane). The number of green, red, and double-positive nuclei were counted and calculated as a percentage of the total number of cells within the image stack.
Longitudinal in vivo imaging of tumor angiogenesis. Optical window chambers were
implanted onto CD-1 nude mice as described above. Prior to sealing the window with a coverslip, a tagRFP-expressing tumor fragment (~1 mm in diameter) was placed into the window. To obtain tumor fragments, a donor animal was injected with 2.5 × 10 5 tagRFP-expressing SCC cells 10 days prior to optical window implantation.
Tumors were removed, cut into small pieces using a scalpel, and fluorescence checked using an Olympus OV110 whole-animal imaging system. For longitudinal imaging of tumor angiogenesis, mice bearing optical windows were anaesthetized using an isoflurane-oxygen mix. Images were acquired 2, 4, 7, and 9 days postimplantation using an Olympus OV110 whole-animal imaging system set to acquire both GFP and RFP signals using the zoom lens set to 1.6× magnification. For image analysis and identification of blood vessels, autofluorescence images acquired using the GFP channel were inverted in ImageJ. The tubness plugin was used to detect blood vessel structures and apply an image mask over these structures. The accuracy of this was checked manually. The vascular density was determined by calculating the percentage of the field of view covered by the vascular image mask. Data were graphed and statistics calculated using Prism.
Results

FAK is required for cell cycle progression and angiogenesis in SCC tumors
We have previously shown using a murine model of skin SCC that depletion of FAK expression can result in immune-mediated tumor regression in syngeneic mice, and a growth delay in immune-deficient mice (17, 24) . We therefore sought to further dissect the complex role of FAK in regulating SCC tumor growth. We measured tumor growth in CD-1 nude mice following injection of 0.25 x 10 6 FAK-deficient cells (SCC FAK-/-) and FAK-deficient cells that re-expressed wild type FAK (SCC FAK-wt) at close to endogenous levels. As previously reported, SCC FAK-/-tumors exhibited a growth delay when compared to SCC FAK-wt tumors (24) (Fig. 1a ) that was associated with an increased tumor doubling time (Fig. 1b) . FAK is a protein that plays a pleiotropic role in regulating cancer development and progression, and we hypothesized that a number of its reported functions, including regulation of proliferation/cell cycle and tumor angiogenesis (1, 2, 30) , may contribute to the observed tumor growth delay in SCC FAK-/-tumors when established on an immune deficient host background. Thus, we set out to use intravital imaging to analyze, in real-time, the cell cycle distribution and kinetics of tumor neo-angiogenesis in SCC FAK-wt and SCC FAK-/-tumors when grown on CD-1 nude mice.
To measure cell cycle distribution in real-time, SCC FAK-wt and SCC FAK-/cells expressing the fluorescent ubiquitination-based cell-cycle indicator (FUCCI) reporter (31) were implanted via intra-dermal injection under dorsal-skinfold imaging windows. The FUCCI probe is based on the differential proteolysis of geminin and cdt1 at specific phases of the cell cycle, allowing differential profiling of cells at G1 (red), G1/S (yellow), and S/G2/M (green) phases. Images of FUCCI-expressing SCC FAK-wt and SCC FAK-/-tumors revealed an increased number of red fluorescent cells in SCC FAK-/-tumors ( Fig. 1c) . Analysis of the proportion of red, yellow, and green nuclei from three-dimensional image stacks acquired 24 hours after tumor cell implantation identified a specific delay in the G1 phase of the cell cycle in SCC FAK-/-tumor cells ( Fig. 1d) .
FAK, expressed in cancer cells, has been reported to influence tumor angiogenesis through regulating the expression of vascular endothelial growth factor (VEGF) (30) .
To ascertain whether defective tumor neo-angiogenesis may also be occurring in SCC (Figs. 1e and 1f) . Thus, SCC FAK-/tumors exhibit defective cell cycle progression and neo-angiogenesis that may contribute to defective tumor growth in CD-1 nude mice.
FAK negatively regulates transcription of IGFBP3
We and others have previously identified that FAK can regulate the expression of secreted proteins that have the potential to act in both an autocrine and paracrine manner to influence cancer cell behavior and the surrounding tumor microenvironment (17, 32, 33) . To investigate whether FAK-dependent regulation of secreted factors in SCC cancer cells could influence cell cycle progression and tumor angiogenesis, we screened for secreted factors implicated in both processes using protein capture arrays. Analysis of 53 secreted factors revealed both positive and negative regulation as a consequence of FAK expression ( Fig. 2a and   Supplementary Fig. 1) . Applying a four-fold cutoff for differential regulation, we identified IGFBP3 as the most highly upregulated protein in SCC FAK-/-conditioned medium, while PDGF-AA, PDGF-AB/BB, FGF-1, and MMP-3 were the most highly upregulated proteins identified in SCC FAK-wt conditioned medium. Using these findings, we focused on IGFBP3, a protein belonging to the family of insulin-like growth factor binding proteins (IGFBPs), as this factor has previously been reported to negatively regulate both cell cycle progression (34, 35) and angiogenesis (36) (37) (38) .
Western blot analysis of conditioned media confirmed an upregulation of IGFBP3 in SCC FAK-/-conditioned samples (Fig. 2b) , and q(RT)-PCR identified similar regulation of Igfbp3 gene transcript levels (Fig. 2c) . Thus, we conclude that FAK negatively regulates the transcription of Igfbp3, leading to reduced levels of extracellular secreted IGFBP3 protein.
IGFBP3 is a member of a family of six proteins, IGFBP1-6 (39). However, only antibody capture pairs specific for IGFBP1, 2, and 3 were present on the protein capture arrays used. Therefore, we sought to determine whether FAK regulated the expression of other IGFBP family members. Employing sequence-specific primers designed for each of the six IGFBPs, we used PCR to screen for expression in cDNA libraries prepared from SCC FAK-wt and SCC FAK-/-cells ( Fig. 2d) . Aside from Igfbp3, only expression of Igfbp4 and Igfbp6 could be detected following 20 cycles of PCR. All primer sets were confirmed to produce single products of the correct size using cDNA prepared from mouse liver (Supplementary Fig. 2) . (q)RT-PCR analysis of Igfbp4 expression revealed no differential regulation ( Fig. 2e) 
, whereas
Igfbp6 expression was observed to exhibit a small but significant decrease in SCC FAK-/-cells when compared to SCC FAK-wt ( Fig. 2f) . Therefore, IGFBP3 was the only IGFBP family member to be negatively regulated in response to FAK expression.
FAK kinase activity is not required for regulation of IGFBP3
There has been considerable interest in targeting FAK function as a cancer therapy, and a number of small molecule FAK kinase inhibitors are now in early-phase clinical development (13) . To determine the role of FAKs kinase activity in regulation of IGFBP3, we tested IGFBP3 protein expression using an SCC FAK-/-cell line in which a FAK kinase-deficient mutant (FAK-kd) had been re-expressed to levels comparable with SCC FAK-wt cells. Anti-IGFBP3 western blotting from conditioned Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. media revealed that IGFBP3 expression in SCC FAK-kd cells was similar to that observed in SCC FAK-wt cells (Fig. 2g) , implying that FAK-dependent regulation of IGFBP3 expression was independent of FAK kinase activity.
IGFBP3 regulates cell cycle progression but not angiogenesis to influence tumor growth
To determine whether increased IGFBP3 expression in SCC FAK-/-cells contributed to the defective growth of SCC FAK-/-tumors, we generated SCC FAK-/-cells with a stable knockdown of IGFBP3 using shRNA (Fig. 3a) . Analysis of subcutaneous tumor growth showed that knock-down of IGFBP3 in SCC FAK-/-cells partially restored tumor growth in vivo (Fig. 3b) , resulting in an average tumor volume of approximately double the size when compared to SCC FAK-/-tumors on day 12.
Using intravital imaging together with the FUCCI cell cycle reporter, we identified that the G1 arrest observed in SCC FAK-/-cells in vivo was overcome following IGFBP3 depletion ( Figs. 3c and 3d) . However, the defect in blood vessel formation was still evident in the SCC FAK-/-shRNA-IGFBP3 tumors as measured by the presence of CD31 + vessels ( Figs. 3e and 3f) . Therefore, IGFBP3 likely contributes to regulation of SCC tumor growth through controlling cell cycle progression, but not angiogenesis. Furthermore, depletion of IGFBP3 in SCC FAK-/-cells was not sufficient to fully restore tumor growth, implying that regulation of angiogenesis is likely also important.
FAK nuclear localization is required for regulation of IGFBP3 transcription
We have recently reported in SCC cells that nuclear FAK can bind to transcription factors and transcriptional regulators with the potential to influence gene expression (17 Igfbp3, we made a series of FAK nuclear targeting mutants according to previously reported findings that identified putative nuclear localization sequences within the F2 lobe of the FERM domain (40) , and expressed these in SCC FAK-/-cells. A total of three nuclear targeting mutants were constructed as follows: (1) replacing lysine residues at positions 216 and 218 with alanines (FAK-216/218). We have previously reported a fourth mutant deficient in nuclear targeting, in which all six of these amino acid residues have been replaced with alanines (17). Biochemical fractionation followed by western blotting was used to assess nuclear/cytoplasmic distribution of the resulting mutants when re-expressed in SCC FAK-/-cells, revealing that all four mutant FAK proteins were deficient in their ability to localize to the nucleus (Fig. 4a) . Given that all of the double mutants appeared as defective in nuclear translocation as the mutant harboring all six mutations, we chose to move forward with these for further analysis. (q)RT-PCR analysis of Igfbp3 expression in cell lines expressing these mutant FAK proteins revealed significantly increased levels of Igfbp3 transcript in all three cell lines (Fig. 4b) , implying a crucial role for FAK nuclear targeting in the transcriptional regulation of Igfbp3. The inability of these mutants to completely restore Igfbp3 transcript levels to that of SCC FAK-/cells is likely the consequence of low levels of residual nuclear FAK (Fig. 4a) .
Runx1 is required for FAK-dependent transcriptional regulation of IGFBP3
To better define the link between nuclear FAK and regulation of Igfbp3 transcription, we next sought to identify transcription factors with predicted binding sites in the promoter of the Igfbp3 gene. Using the DECODE database (Qiagen), we generated a list of transcription factors predicted by text mining to bind between 20 kb upstream and 10 kb downstream of the human transcription start site ( Fig. 4c) . Of these transcription factors, three -Sp1, Runx1, and components of the transcription factor IID complex (TFIID)were detected by mass spectrometry in a nuclear FAK interactome in SCC cells (Fig. 4c, dark grey bars) (17) . We noted that the transcription factor Runx1, which has been reported to regulate Igfbp3 gene expression (41) , had the most Igfbp3 promoter binding sites predicted by text mining (Fig. 4c) . Moreover, Runx1 was not among the top transcription factors predicted to bind to the gene promoters of the other secreted proteins in the cluster highly upregulated in SCC FAK-/-conditioned medium (Supplementary Fig. 1, top cluster, and Supplementary Fig. 3 ), suggesting that these other angiogenesis-related proteins may be transcriptionally regulated by a distinct mechanism to Igfbp3.
Using shRNA-mediated stable knockdown of Runx1 expression, we next determined whether Runx1 was required for IGFBP3 expression in SCC FAK-wt and SCC FAK-/-cells. Biochemical fractionation followed by western blotting confirmed a substantial knockdown of Runx1 expression in both SCC FAK-wt shRNA-Runx1 and SCC FAK-/-shRNA-Runx1 cells (Fig. 4d ) when compared to controls. Analysis of Igfbp3 expression in these cell lines using (q)RT-PCR showed a loss of Igfbp3 gene expression in SCC FAK-/-shRNA-Runx1 cells, reverting expression levels down to those observed in SCC FAK-wt vector-only control cells (Fig. 4e) . Thus, Runx1 is required for increased Igfbp3 transcription following FAK loss in SCC cells. Using an independent method of expression knockdown, similar results were observed following depletion of Runx1 using siRNAs (Supplementary Fig. 4) . 
FAK is in a complex with Runx1 in the nucleus
Analysis of Runx1 expression in SCC FAK-wt and FAK-/-cells revealed that Runx1
is exclusively expressed in the nucleus, and that its expression level is not regulated by FAK (Fig. 4d) . Hence, regulation of Runx1 expression / degradation is unlikely the mechanism through which FAK controls Runx1 transcriptional activity in SCC cells. Runx1 can act as either a transcriptional activator or repressor, and the composition of the proteins interacting with Runx1 at a given gene can modulate this function (18) . Using a mass spectrometry dataset of the nuclear FAK interactome in SCC cells (17) we identified a potential FAK / Runx1 interaction. Coimmunoprecipitation of Runx1 and FAK in SCC FAK-wt but not in SCC FAK-/-cells confirmed a novel association between FAK and Runx1 ( Figs. 5a and 5b) . Thus, nuclear FAK exists in complex with Runx1 under steady-state conditions in SCC cancer cells.
A key mechanism of Runx1 regulation is post-translational modification.
Runx1 interacts with a number of proteins including kinases, histone acetyltransferases, arginine methyltransferases, and histone deacetylases that can posttranslationally modify Runx1, switching it between transcriptional activation and repression (18, 19) . To further explore how FAK influences Runx1 function, we examined the Runx1 interaction landscape in the context of FAK. To do this, we constructed a Runx1 protein interaction network in silico, onto which we mapped the experimentally derived nuclear FAK interactome. This integrated interaction network identified a subnetwork of Runx1 regulators and associated proteins that interact with FAK in the nuclei of SCC cells ( Fig. 5c and Supplementary Fig. 5 ). Interestingly, a number of these proteins, including DNA (cytosine-5)-methyltransferase 1 (Dnmt1), Sin3a, Histone deacetylases 1, 2, and 3 (HDAC1, 2, and 3), and Nuclear receptor Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-0418 activity (18, 19) . Therefore, nuclear FAK interacts with proteins that can regulate the post-translational modification and transcriptional function of Runx1. KEGG analysis also identified an enrichment for proteins with roles in the cell cycle ( Fig. 5d and   Supplementary Table 1) , consistent with a complex that may play a wider role in the regulation of cell cycle progression.
To determine whether FAK regulated Runx1 tyrosine phosphorylation, we used immunoprecipitation of tyrosine phosphorylated proteins from SCC FAK-wt and FAK-/-cell lysates, followed by western blotting and detection with an anti-Runx1 antibody. No regulation of Runx1 tyrosine phosphorylation was observed (Fig. 5e) .
To assess Runx1 post-translational modification on a wider scale we performed 2D gel electrophoresis using nuclear extracts prepared from SCC FAK-wt and FAK-/cells, and probed these gels with an anti-Runx1 antibody. This identified a number of potential differences in both the migration and intensity of spots detected (Fig. 5f, red arrows highlight changes), consistent with an altered state of post-translational modification.
We next investigated whether FAK regulated proteins associated with the post-translational modification of Runx1. Based on data presented in Fig. 5c , we focused on Sin3a, a transcriptional co-repressor known to interact with a number of HDACs (42) and suppress Runx1 transcriptional activity (43) . Western blotting using an anti-Sin3a antibody identified reduced Sin3a levels in the nucleus of SCC FAK-/-cells when compared to SCC FAK-wt cells (Fig. 5g) . Coimmunoprecipitation from SCC FAK-wt and FAK-/-nuclear extracts confirmed a novel association between Sin3a and FAK in SCC FAK-wt cells (Fig. 5h) . Thus, FAK is in complex with and regulates the nuclear levels of a Sin3a.
Immunoprecipitation of Runx1 from SCC FAK-wt and FAK-/-nuclear extracts
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Author Manuscript Published OnlineFirst on August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-0418 followed by western blotting and detection with an anti-Sin3a antibody confirmed an association between Runx1 and Sin3a in SCC FAK-wt cells (Fig. 5i) . No interaction was observed in SCC FAK-/-cells. Therefore, we propose that one potential mechanism through which FAK may influence the post-translational modification and transcriptional activity of Runx1, is through regulating the expression and subsequent recruitment of Sin3a to Runx1 transcriptional complexes.
Discussion
Numerous studies have demonstrated the importance of FAK in regulating tumor cell behavior, which has largely been linked to its role in integrating signals from adhesion sites and growth factor receptors at the cell periphery to control cell adhesion, migration and survival (1, 2) . In addition, it is now becoming clear that FAK can also play a role within the nucleus to control gene expression (14, 17, 44) . However, the mechanisms underpinning this function remain to be fully characterized. A number of nuclear FAK binding proteins have now been identified including the transcription factors p53 and GATA4 (14, 16) . Recently, we have shown that nuclear FAK is associated with chromatin and interacts with transcription factors, including the TBPassociated factor TAF9, and transcriptional regulators reported or predicted to regulate expression of the chemokine Ccl5. In doing so, it controls the transcription of chemokines that regulate the composition of the immuno-suppressive tumor environment required to evade the CD8 + T-cell anti-tumor immune response (17) .
Here, we identify a novel interaction between nuclear FAK and the transcription factor Runx1. We show that nuclear FAK controls the Runx1 dependent expression of IGFBP3, which in turn regulates cell cycle progression and SCC tumor growth in vivo. Further, we identify that FAK interacts with and regulates the nuclear levels of Sin3a, and that FAK is required for recruitment of Sin3a into complex with Runx1. Therefore, nuclear FAK can regulate transcription factor activity, potentially via recruitment of proteins to transcriptional complexes that can alter transcription factor post-translational modification, thereby controlling expression of specific genes that can play an important role in regulating both tumor cell behavior, and how tumor cells influence the composition of the tumor immune environment.
Runx1 is a transcription factor with an important role in both normal development and disease (20, 21) . De-regulation of Runx1 function contributes to the development of hematological malignances, and in solid epithelial cancers, it has been identified as both a tumor promoter and a tumor suppressor (19) . Runx1 can either activate or repress transcription depending on the composition of the protein complexes with which it is associated at a given gene (18) , and this likely contributes to the complexity of its role in regulating tumorigenesis. It is known to interact with an array of proteins including kinases, histone acetyltransferases, arginine methyltransferases, histone deacetylases, and ubiquitin ligases, all of which can post-translationally modify Runx1 to regulate its transcriptional function (18, 19) . Using mass spectrometry, we show that FAK interacts with a number of these proteins including Dnmt1, Sin3a, HDACs 1, 2, and 3, and NCoR1 and 2, all of which are known to repress Runx1 function (18, 19) . Co-immunoprecipitation experiments confirmed a novel interaction between Sin3a and FAK, and further identified a requirement for FAK to promote interaction of Runx1 with Sin3a. Supporting this as a potential mechanism of FAK-dependent Runx1 regulation, 2D gel analysis of nuclear extracts from SCC FAK-wt and FAK-/-cells using an anti-Runx1 antibody identified several protein species that show differential migration, consistent with altered post- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-0418 translational modification. Notably, post-translational modification is an important mechanism in the general regulation of transcription factor function (45) . Thus, we conclude that this may represent a previously unknown mode of FAK-dependent regulation of gene expression.
FAK is known to regulate a number of cellular processes important for the malignant phenotype (1, 2) . Here, we identify a new role for nuclear FAK in regulation of SCC cell cycle progression in vivo via controlling Runx1-dependent expression of IGFBP3. IGFBP3 has been linked to cell cycle arrest in tumor cells previously where a G1 arrest was accompanied by reduction in a number of cyclins, including cyclin D1, CDKs, and increased p21 expression (34, 35) . IGFBP3 has also been linked to regulation of angiogenesis (36) (37) (38) . However, knockdown of IGFBP3 in the SCC cells had no effect on tumor angiogenesis. Analysis of secreted proteins present in SCC conditioned media identified a number of changes including multiple factors that can influence tumor angiogenesis, implying that other factors may be more important in the regulation of angiogenesis in our SCC model. Interestingly, analysis of the predicted transcription factor binding sites in the promoters of other angiogenesis-related genes regulated by FAK identified that their mechanism of regulation is likely distinct to that of IGFBP3, highlighting the potential mechanistic diversity underpinning FAK-dependent transcriptional regulation. 
